The Norwegian Immunotherapy in Multiple Myeloma Study

NCT06855121 · clinicaltrials.gov ↗

RECRUITING

Status

400

Enrollment

OTHER

Sponsor class

Conditions

Myeloma Multiple
Plasma Cell Leukemia
AL Amyloidosis

Interventions

DRUG: Teclistamab
DRUG: Elranatamab
BIOLOGICAL: Ciltacabtagene Autoleucel
DRUG: Talquetamab
BIOLOGICAL: Idecabtagene vicleucel

Sponsor

St. Olavs Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]